Myotonic Dystrophy: Therapeutic Strategies for the Future

Neurotherapeutics

Volumn 5, Issue 4, 2008, Pages 592-600

  Wheeler, Thurman M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

CUGBP1; MBNL1; myotonia; Myotonic dystrophy; RNA disease; RNA toxicity; spliceopathy

Indexed keywords

ALPHA SARCOGLYCAN; ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; CREATINE; DEACETYLASE INHIBITOR; DYSTROPHIN; ENZYME INHIBITOR; MBNL1 PROTEIN; MECASERMIN RINFABATE; MEXILETINE; MUTANT PROTEIN; MYO 029; PARVOVIRUS VECTOR; PRASTERONE; PROTEIN; RECOMBINANT SOMATOMEDIN C; RNA; RNA BINDING PROTEIN; SMALL INTERFERING RNA; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; CELL NUCLEUS; CLINICAL TRIAL; GENE EXPRESSION; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LIMB GIRDLE MUSCULAR DYSTROPHY; MUSCLE ATROPHY; MYOTONIA; MYOTONIC DYSTROPHY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TOXICITY;

ANIMALS; GENE THERAPY; HUMANS; MUSCLE, SKELETAL; MYOTONIC DYSTROPHY; RNA;

EID: 53049100021     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.08.001     Document Type: Article

References (71)

1. Harper P.S. Myotonic dystrophy. 2nd ed. (1989), W.B. Saunders, London, Philadelphia
2. Brook J.D., McCurrach M.E., Harley H.G., et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member [Erratum in: Cell 1992;69:385]. Cell 68 (1992) 799-808
3. Liquori C.L., Ricker K., Moseley M.L., et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293 (2001) 864-867
4. Taneja K.L., McCurrach M., Schalling M., Housman D., and Singer R.H. Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J Cell Biol 128 (1995) 995-1002
5. n expansions associated with myotonic dystrophy. EMBO J 19 (2000) 4439-4448
6. Kanadia R.N., Johnstone K.A., Mankodi A., et al. A muscleblind knockout model for myotonic dystrophy. Science 302 (2003) 1978-1980
7. Lin X., Miller J.W., Mankodi A., et al. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet 15 (2006) 2087-2097
8. Philips A.V., Timchenko L.T., and Cooper T.A. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 280 (1998) 737-741
9. Savkur R.S., Philips A.V., and Cooper T.A. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 29 (2001) 40-47
10. Ho T.H., Charlet-B N., Poulos M.G., Singh G., Swanson M.S., and Cooper T.A. Muscleblind proteins regulate alternative splicing. EMBO J 23 (2004) 3103-3112
11. Mankodi A., Takahashi M.P., Jiang H., et al. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell 10 (2002) 35-44
12. Charlet-B N., Savkur R.S., Singh G., Philips A.V., Grice E.A., and Cooper T.A. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell 10 (2002) 45-53
13. Savkur R.S., Philips A.V., Cooper T.A., et al. Insulin receptor splicing alteration in myotonic dystrophy type 2. Am J Hum Genet 74 (2004) 1309-1313
14. Osborne R.J., and Thornton C.A. RNA-dominant diseases. Hum Mol Genet 15 Spec No 2 (2006) R162-R169
15. Trip J., Drost G., van Engelen B.G., and Faber C.G. Drug treatment for myotonia. Cochrane Database Syst Rev 1 (2006) CD004762
16. Martens W.B., Moxley III R.T., Logigian E.L., et al. Mexiletine: effective antimyotonia treatment in myotonic dystrophy type 1. Neurology 64 (2005) A413 (abstract)
17. Logigian E.L., Ciafaloni E., Quinn L.C., et al. Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy. Muscle Nerve 35 (2007) 479-485
18. Halliday D., Ford G.C., Edwards R.H., Rennie M.J., and Griggs R.C. In vivo estimation of muscle protein synthesis in myotonic dystrophy. Ann Neurol 17 (1985) 65-69
19. Griggs R.C., Jozefowicz R., Kingston W., Nair K.S., Herr B.E., and Halliday D. Mechanism of muscle wasting in myotonic dystrophy. Ann Neurol 27 (1990) 505-512
20. Griggs R.C., Pandya S., Florence J.M., et al. Randomized controlled trial of testosterone in myotonic dystrophy. Neurology 39 (1989) 219-222
21. Walter M.C., Reilich P., Lochmüller H., et al. Creatine monohydrate in myotonic dystrophy: a double-blind, placebo-controlled clinical study. J Neurol 249 (2002) 1717-1722
22. Schneider-Gold C., Beck M., Wessig C., et al. Creatine monohydrate in DM2/PROMM: a double-blind placebo-controlled clinical study. Neurology 60 (2003) 500-502
23. Tarnopolsky M., Mahoney D., Thompson T., Naylor H., and Doherty T.J. Creatine monohydrate supplementation does not increase muscle strength, lean body mass, or muscle phosphocreatine in patients with myotonic dystrophy type 1. Muscle Nerve 29 (2004) 51-58
24. Sugino M., Ohsawa N., Ito T., et al. A pilot study of dehydroepiandrosterone sulfate in myotonic dystrophy. Neurology 51 (1998) 586-589
25. Musarò A., McCullagh K., Paul A., et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 27 (2001) 195-200
26. Barton E.R., Morris L., Musaro A., Rosenthal N., and Sweeney H.L. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol 157 (2002) 137-148
27. Vlachopapadopoulou E., Zachwieja J.J., Gertner J.M., et al. Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy: a clinical research center study. J Clin Endocrinol Metab 80 (1995) 3715-3723
28. Boonen S., Rosen C., Bouillon R., et al. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study. J Clin Endocrinol Metab 87 (2002) 1593-1599
29. Clemmons D.R., Moses A.C., Sommer A., et al. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm IGF Res 15 (2005) 265-274
30. Heatwole C.R., Martens W., Quinn C., et al. Effects of IPLEX in myotonic dystrophy type 1. Neurology 68 (2007) A404-A405 (abstract)
31. McPherron A.C., and Lee S.J. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci U S A 94 (1997) 12457-12461
32. McPherron A.C., Lawler A.M., and Lee S.J. Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature 387 (1997) 83-90
33. Schuelke M., Wagner K.R., Stolz L.E., et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350 (2004) 2682-2688
34. Mosher D.S., Quignon P., Bustamante C.D., et al. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet 3 (2007) e79
35. Shelton G.D., and Engvall E. Gross muscle hypertrophy in whippet dogs is caused by a mutation in the myostatin gene. Neuromuscul Disord 17 (2007) 721-722
36. Wagner K.R., McPherron A.C., Winik N., and Lee S.J. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 52 (2002) 832-836
37. Bogdanovich S., Krag T.O., Barton E.R., et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 420 (2002) 418-421
38. Minetti G.C., Colussi C., Adami R., et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med 12 (2006) 1147-1150
39. Welle S., Bhatt K., and Pinkert C.A. Myofibrillar protein synthesis in myostatin-deficient mice. Am J Physiol Endocrinol Metab 290 (2006) E409-E415
40. Lee S.J. Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 20 (2004) 61-86
41. McPherron A.C., and Lee S.J. Suppression of body fat accumulation in myostatin-deficient mice. J Clin Invest 109 (2002) 595-601
42. Wagner K.R., Fleckenstein J.L., Amato A.A., et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 63 (2008) 561-571
43. Lachey J., Pullen A., Pearsall R., and Seehra J. Novel myostatin inhibitors increase muscle mass in wild-type and mdx mice. Neuromuscul Disord 17 (2007) 785 (abstract)
44. Morcos P.A. Achieving targeted and quantifiable alteration of mRNA splicing with Morpholino oligos. Biochem Biophys Res Commun 358 (2007) 521-527
45. Haidet A.M., Rizo L., Handy C., et al. Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci U S A 105 (2008) 4318-4322
46. Orengo J.P., Chambon P., Metzger D., Mosier D.R., Snipes G.J., and Cooper T.A. Expanded CTG repeats within the DMPK 3′ UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc Natl Acad Sci U S A 105 (2008) 2646-2651
47. Lueck J.D., Mankodi A., Swanson M.S., Thornton C.A., and Dirksen R.T. Muscle chloride channel dysfunction in two mouse models of myotonic dystrophy. J Gen Physiol 129 (2007) 79-94
48. Wheeler T.M., Lueck J.D., Swanson M.S., Dirksen R.T., and Thornton C.A. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest 117 (2007) 3952-3957
49. Lu Q.L., Rabinowitz A., Chen Y.C., et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A 102 (2005) 198-203
50. Alter J., Lou F., Rabinowitz A., et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12 (2006) 175-177
51. van Deutekom J.C., Janson A.A., Ginjaar I.B., et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357 (2007) 2677-2686
52. Li Y.F., and Morcos P.A. Design and synthesis of dendritic molecular transporter that achieves efficient in vivo delivery of morpholino antisense oligo. Bioconjug Chem 19 (2008) 1464-1470
53. Jearawiriyapaisarn N., Moulton H.M., Buckley B., et al. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 16 (2008) 1624-1629
54. Dansithong W., Paul S., Comai L., and Reddy S. MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1 [Erratum in: J Biol Chem 2005;280:20176]. J Biol Chem 280 (2005) 5773-5780
55. Kanadia R.N., Shin J., Yuan Y., et al. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci U S A 103 (2006) 11748-11753
56. de Haro M., Al-Ramahi I., De Gouyon B., et al. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1. Hum Mol Genet 15 (2006) 2138-2145
57. Gregorevic P., Blankinship M.J., Allen J.M., et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 10 (2004) 828-834
58. Jiang H., Mankodi A., Swanson M.S., Moxley R.T., and Thornton C.A. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol Genet 13 (2004) 3079-3088
59. Wheeler T.M., Krym M.C., and Thornton C.A. Ribonuclear foci at the neuromuscular junction in myotonic dystrophy type 1. Neuromuscul Disord 17 (2007) 242-247
60. Wang G.S., Kearney D.L., De Biasi M., Taffet G., and Cooper T.A. Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy. J Clin Invest 117 (2007) 2802-2811
61. Kuyumcu-Martinez N.M., Wang G.S., and Cooper T.A. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell 28 (2007) 68-78
62. Furling D., Doucet G., Langlois M.A., et al. Viral vector producing antisense RNA restores myotonic dystrophy myoblast functions. Gene Ther 10 (2003) 795-802
63. Langlois M.A., Lee N.S., Rossi J.J., and Puymirat J. Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts. Mol Ther 7 (2003) 670-680
64. Mahadevan M.S., Yadava R.S., Yu Q., et al. Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat Genet 38 (2006) 1066-1070
65. Krol J., Fiszer A., Mykowska A., Sobczak K., de Mezer M., and Krzyzosiak W.J. Ribonuclease dicer cleaves triplet repeat hairpins into shorter repeats that silence specific targets. Mol Cell 25 (2007) 575-586
66. Margolis J.M., Schoser B.G., Moseley M.L., Day J.W., and Ranum L.P. DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression. Hum Mol Genet 15 (2006) 1808-1815
67. Jones J.O., and Diamond M.I. Design and implementation of cell-based assays to model human disease. ACS Chem Biol 2 (2007) 718-724
68. Desai U.A., Pallos J., Ma A.A., et al. Biologically active molecules that reduce polyglutamine aggregation and toxicity. Hum Mol Genet 15 (2006) 2114-2124
69. Garcia-Lopez A., Monferrer L., Garcia-Alcover I., Vicente-Crespo M., Alvarez-Abril M.C., and Artero R.D. Genetic and chemical modifiers of a CUG toxicity model in Drosophila. PLoS ONE 3 (2008) e1595
70. Orengo J.P., Bundman D., and Cooper T.A. A bichromatic fluorescent reporter for cell-based screens of alternative splicing. Nucleic Acids Res 34 (2006) e148
71. Childs-Disney J.L., Wu M., Pushechnikov A., Aminova O., and Disney M.D. A small molecule microarray platform to select RNA internal loop-ligand interactions. ACS Chem Biol 2 (2007) 745-754